**12th Annual UCI Neuromuscular Colloquium**

May 24, 2024

**Purpose**

This colloquium is designed to encourage an atmosphere of collaboration and interaction between the various neuromuscular specialists in the US, Canada and internationally. It is a forum to discuss the latest topics and advances in neuromuscular medicine and review interesting and challenging cases, with several live patient presentations. Such activities are aimed to improve patient care by promoting closer research collaboration and the development of new research projects between the various groups and institutions.

**Target Audience**

Specialties – Neurology, Pathology & Laboratory Medicine, Pediatrics, Genetic And Genomic Medicine, Neurology

Professions – Physician, Non-Physician, Allied Health Professional, Audiologist, Medical Assistant, Medical Student, Nurse, Nurse Practitioner, Pharmacist, Physical Therapist, Physician Assistant, Resident Physician, Social Worker, Speech-Language Pathologist

**Activity Objectives**

1 Identify different clinical presentations and patterns of involvement in neuromuscular diseases.

2 Understand current standards and guidelines for management of neuromuscular disorders.

3 Understand genetic basis of inherited myopathies and advancements in gene therapies.

4 Understand the changing landscape of myasthenia gravis treatment in light of recent development of targeted therapies such as complement inhibition and neonatal Fc receptor (FcRn) blockade.

5 Identify current and emerging therapies in spinal muscular atrophy.

6 Discuss ongoing clinical trials in Amyotrophic Lateral Sclerosis including gene targeted and cell-based therapies.

7 Identify features on muscle pathology that help distinguish distinct subtypes of inflammatory muscle diseases.

**Accreditation Statement**

The University of California, Irvine School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**Designation Statement**

The University of California, Irvine School of Medicine designates this Learning from teaching,Live Activity for a maximum of 8.00 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**California Assembly Bill 1195 and 241**

This activity is in compliance with California Assembly Bill 1195 and 241, which require CME activities with patient care components to include curriculum in the subjects of cultural and linguistic competency & implicit bias. It is the intent of AB 1195 and AB 241 to encourage physicians and surgeons, CME providers in the State of California, and the Accreditation Council for Continuing Medical Education to meet the cultural and linguistic concerns of a diverse patient population and reduce health disparities through appropriate professional development. Please see the CME website, <https://www.meded.uci.edu/CME/> for AB 1195 and AB 241 resources.









**Faculty & Planner Disclosures**

University of California, Irvine School of Medicine Continuing Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| Mindi Word | Other Planning Committee Member | Nothing to disclose - 12/15/2023 |
| Tahseen Mozaffar,, MD, Professor | Course Director, Faculty | Grant or research support-Alexion Pharmaceuticals|Consulting Fee-Amicus|Grant or research support-Amicus|Consulting Fee-Sanofi|Grant or research support-Sanofi S.A.|Advisor-Maze Therapeutics|Grant or research support-Spark Therapeutics (Relationship has ended)|Consulting Fee-Cabaletta (Relationship has ended)|Grant or research support-AnnJi|Grant or research support-Ask Bio|Consulting Fee-Horizon Therapeutics|Grant or research support-Cabaletta|Consulting Fee-Janssen (Any division) (Relationship has ended)|Consulting Fee-Argenx|Grant or research support-Argenx|Consulting Fee-Merck (Any division)|Honoraria-Muscular Dystrophy Association|Consulting Fee-Regeneron Pharmaceuticals, Inc.|Consulting Fee-UCB|Consulting Fee-Horizon Pharmaceuticals|Grant or research support-Astellas (Any division)|Consulting Fee-Alexion Pharmaceuticals - 12/16/2023 |
| Ali A Habib, MD | Course Director, Faculty | Grant or research support-argenx|Grant or research support-Alexion Pharmaceuticals|Grant or research support-UCB|Grant or research support-CabalettaBio|Grant or research support-Genentech (Any division)|Grant or research support-Immunovant|Grant or research support-Regeneron Pharmaceuticals, Inc.|Grant or research support-VielaBio-Horizon|Speakers Bureau-Alexion Pharmaceuticals|Speakers Bureau-UCB|Speakers Bureau-argenx|Membership on Advisory Committees or Review Panels, Board Membership, etc.-argenx|Membership on Advisory Committees or Review Panels, Board Membership, etc.-UCB|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Roche (Any division)|Paid consultant-NMDPharma|Paid consultant-Alpine Immune Sciences|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Immunis Biomedical - 12/16/2023 |
| Namita Goyal, MD | Course Director, Faculty | Grant or research support-Abcuro|Grant or research support-Amylyx (Relationship has ended)|Grant or research support-Alexion|Grant or research support-Annexon|Grant or research support-Brainstorm Cell Therapeutics (Relationship has ended)|Grant or research support-Calico|Grant or research support-Fulcrum|Grant or research support-Janssen|Grant or research support-Medicinova|Grant or research support-MT Pharma (Relationship has ended)|Grant or research support-PTC therapeutics|Grant or research support-Sanofi|Speakers Bureau-Argenx - 12/16/2023 |
| Mari Perez-Rosendahl, MD | Faculty | Nothing to disclose - 12/15/2023 |
| Anne M Connolly, MD, FAAN | Faculty | Advisor-Sarepta Therapeutics|Advisor-Edgewise Therapeutics|Grant or research support-Scholar Rock|Grant or research support-Biohaven|Grant or research support-Novartis - 02/17/2024 |
| Megan A Waldrop, MD | Faculty | Advisor-Novartis Corporation Pharmaceuticals (Relationship has ended)|Consulting Fee-Sarepta Therapeutics|Grant or research support-Sarepta Therapeutics|Grant or research support-Novartis Corporation Pharmaceuticals|Grant or research support-Astelllas Gene Therapies (Relationship has ended) - 02/20/2024 |
| Prepageran Narayanan, MD | Faculty | Nothing to disclose - 02/23/2024 |
| Nicholas J. Silvestri, MD | Faculty |  |
| Katherine Ruzhansky, MD | Faculty | Advisor-Alexion Pharmaceuticals|Advisor-Argenx|Advisor-Amylyx (Relationship has ended)|Advisor-UCB|Advisor-Immunovant|Grant or research support-Alexion Pharmaceuticals (Relationship has ended)|Grant or research support-Argenx (Relationship has ended)|Grant or research support-UCB|Grant or research support-Janssen (Any division)|Grant or research support-Immunovant - 03/01/2024 |

**Agenda**

**[INSERT AGENDA HERE MANUALLY]**

**Acknowledgement of Commercial Support**

No commercial support has been received for this activity.